Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Andrew Asher Protter"'
Autor:
Mark A. Schroeder, Ann C. Mladek, Gaspar J. Kitange, Yuqiao Shen, Brett L. Carlson, Ryo Kawashima, Andrew Asher Protter, Sani H. Kizilbash, Shiv K. Gupta, Kenneth J. Chang, Ying Feng, Karen E. Parrish, Jann N. Sarkaria, Paul A. Decker, Katrina K. Bakken, William F. Elmquist
Publikováno v:
Molecular Cancer Therapeutics. 16:2735-2746
Poly ADP-ribose polymerase (PARP) inhibitors, including talazoparib, potentiate temozolomide efficacy in multiple tumor types; however, talazoparib-mediated sensitization has not been evaluated in orthotopic glioblastoma (GBM) models. This study eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8cfb79058b90a96c0c997df3a90f4af3
https://doi.org/10.1158/1535-7163.mct-17-0365
https://doi.org/10.1158/1535-7163.mct-17-0365
Autor:
Zhimin Guo, Connie J. Rogers, Andrew Asher Protter, David Apelian, Thomas H. King, James W. Hodge, Benedetto Farsaci, Andressa Ardiani
Publikováno v:
Clinical Cancer Research. 19:6205-6218
Purpose: Enzalutamide, a second-generation androgen antagonist, was approved by the U.S. Food and Drug Administration (FDA) for castration-resistant prostate cancer (CRPC) treatment. Immunotherapy has been shown to be a promising strategy for prostat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90ba0b988aa58f4b8eec6962731434ed
https://doi.org/10.1158/1078-0432.ccr-13-1026
https://doi.org/10.1158/1078-0432.ccr-13-1026
Autor:
Andrew Asher Protter, Iván E. Alfaro, Sebastian Bernales, Javier Sanchez Guerrero, Francisco Gómez
Publikováno v:
The Prostate. 73:1291-1305
BACKGROUND Enzalutamide (formerly MDV3100 and available commercially as Xtandi®), a novel androgen receptor (AR) signaling inhibitor, blocks the growth of castration-resistant prostate cancer (CRPC) in cellular model systems and was shown in a clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe5223d08a792bd1aadca86fe0702f1b
https://doi.org/10.1002/pros.22674
https://doi.org/10.1002/pros.22674
Autor:
Iván E. Alfaro, Prashant Bharadwaj, Shulin Ju, Soong Ho Kim, Gregory A. Petsko, A. Friss, Dagmar Ringe, John W. Steele, Zhenyu Yue, Renae Barr, Luz Delgado, Veer Bala Gupta, Aryeh Stock, J. Liken, Michelle E. Ehrlich, Rong Wang, Andrew Asher Protter, Sebastian Bernales, Ralph N. Martins, Sam Gandy, M.L. Lachenmayer, Giuseppe Verdile, Georgia Dolios
Publikováno v:
Molecular psychiatry
Latrepirdine (Dimebon; dimebolin) is a neuroactive compound that was associated with enhanced cognition, neuroprotection and neurogenesis in laboratory animals, and has entered phase II clinical trials for both Alzheimer's disease and Huntington's di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a635836dd43e6a66c4e3e550934c2684
https://doi.org/10.1038/mp.2012.115
https://doi.org/10.1038/mp.2012.115
Autor:
Prashant Bharadwaj, John W. Steele, Paul Szabo, Joseph D. Buxbaum, Shulin Ju, M. L. Lachenmayer, J. Liken, Michelle E. Ehrlich, Iván E. Alfaro, Luz Delgado, Paul E. Fraser, Sam Gandy, Giuseppe Verdile, David Westaway, Norman R. Relkin, Veer Bala Gupta, Georgia Dolios, Sebastian Bernales, Dagmar Ringe, A. Friss, Renae Barr, Aryeh Stock, Zhenyu Yue, Soong Ho Kim, Rong Wang, P. St. George-Hyslop, Charles G. Glabe, Andrew Asher Protter, Ralph N. Martins, Gregory A. Petsko
Publikováno v:
Molecular Psychiatry. 18:889-897
Latrepirdine (Dimebon) is a pro-neurogenic, antihistaminic compound that has yielded mixed results in clinical trials of mild to moderate Alzheimer's disease, with a dramatically positive outcome in a Russian clinical trial that was unconfirmed in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f28566be02425084e1be66ed881eb8e5
https://doi.org/10.1038/mp.2012.106
https://doi.org/10.1038/mp.2012.106
Autor:
Stephen Chang, Stephen E. Daniels, Peter McL. Black, Sandra E. Tong, Andrew Asher Protter, Paul J. Desjardins
Publikováno v:
The Journal of Clinical Pharmacology. 52:717-728
SCIO-469 is a selective p38α mitogen-activated protein kinase (MAPK) inhibitor for preclinical models of acute pain. This prospective, double-blind, randomized clinical study compared efficacy and safety of oral SCIO-469, ibuprofen, and placebo in p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28b2710059339063d1fabae86b8fe3e3
https://doi.org/10.1177/0091270011405496
https://doi.org/10.1177/0091270011405496
Autor:
Damir Herman, Vernon T. Phan, Pek Yee Lum, Sidney P. Elmer, Traci Mizuno, Andrew Asher Protter, Brent Louie, Johan A. Grahnen, Kevin H. Kim
Publikováno v:
Journal of Clinical Oncology. 36:e14575-e14575
e14575Background: Reactive oxygen species (ROS) homeostasis is crucial for cell survival. Drugs that possess anti-tumor effects by suppressing ROS metabolism in cancer cells have potential as a new...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4cd8c6f8737ead781c3c8a65576cd65b
https://doi.org/10.1200/jco.2018.36.15_suppl.e14575
https://doi.org/10.1200/jco.2018.36.15_suppl.e14575
Autor:
Olivia Farias, Andrew Asher Protter, Ashu Gupta, Kakoli Mukherjee, Vernon T. Phan, Eduardo Riquelme, Mohd. Raja, Jeffrey N. Lindquist, Hirdesh Uppal, Roopa Rai
Publikováno v:
Molecular Cancer Research. 15:B30-B30
Purpose: To investigate the effects of talazoparib alone and in combination with temozolomide (TMZ) on prostate cancer cells Introduction: Talazoparib is a potent, orally bioavailable, small molecule inhibitor of PARP (poly-ADP ribose polymerase) enz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e410848af4c509a7a8eab6c65dac4a7
https://doi.org/10.1158/1557-3125.dnarepair16-b30
https://doi.org/10.1158/1557-3125.dnarepair16-b30
Autor:
Anthony D. Elias, Nicole S. Spoelstra, Annie Jean, Satyanarayana Medicherla, Paul Jedlicka, Dawn R. Cochrane, Ann D. Thor, Erin N. Howe, Nicholas C. D'Amato, Andrew Asher Protter, Iván E. Alfaro, Jennifer K. Richer, Kathleen C. Torkko, Diana M. Cittelly, Emma McCullagh, Francisco Gómez, Susan M. Edgerton, Sebastian Bernales, Britta M. Jacobsen, Javier Sanchez Guerrero
Publikováno v:
Breast Cancer Research : BCR
Introduction The androgen receptor (AR) is widely expressed in breast cancers and has been proposed as a therapeutic target in estrogen receptor alpha (ER) negative breast cancers that retain AR. However, controversy exists regarding the role of AR,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d66d2f1d6c2061c70d9879ed9d45f22f
http://europepmc.org/articles/PMC3978822
http://europepmc.org/articles/PMC3978822
Autor:
Paul Jedlicka, Britta M. Jacobsen, Andrew Asher Protter, Nicholas C. D'Amato, Jennifer K. Richer, Haihua Gu, Sebastian Bernales, Ann D. Thor, Dawn R. Cochrane, Anthony D. Elias, Kathleen C. Torkko, Susan M. Edgerton
Publikováno v:
Cancer Research. 73:4756-4756
Background: In breast cancers, the androgen receptor (AR) is more widely expressed than estrogen receptor alpha (ER) or progesterone receptor (PR), and AR has recently emerged as a useful marker for refinement of breast cancer subtype classification.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7725fe05a65be602528dec4864e6ea9c
https://doi.org/10.1158/1538-7445.am2013-4756
https://doi.org/10.1158/1538-7445.am2013-4756